Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07227584 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ALL Backbone in AYAs

StatusRecruiting
PhasePhase 2
Started2026-04-03
View on ClinicalTrials.gov ↗

Amendment history

2026-08-14
notable
Study Status, Contacts/Locations v1
Recruitment opened
Start dateestimated 2026-04→confirmed 2026-04-03
Study sites0→1
2025-11-10
minor
Original filing
The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of immunotherapy drug) * cyclophosphamide (a type of chemotherapy drug) * cytarabine (a type of antineoplastic agent) * dexamethasone (a type of synthetic glucocorticoid) * doxorubicin (a type of antineoplastic agent) * etoposide (a type of antineoplastic agent) * mercaptopurine (a type of antineoplastic agent) * methotrexate (a type of chemotherapy drug) * pegaspargase (a type of antineoplastic agent) * vincristine (a type of antineoplastic agent)
Trial Details
NCT Number NCT07227584
Lead Sponsor Dana-Farber Cancer Institute
Conditions Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia
Enrollment 67 participants
Start Date 2026-04-03
Primary Completion 2030-07-31 (estimated)
Study Completion 2035-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-17